CDK9 and hematologic malignancies: pioneering novel therapeutic approaches
Hanie Raufi, Pouya Zahmatkesh, Sahar Safaei, Ata Bahadori, Saeed Solali · 2026
Read CDK9 and hematologic malignancies: pioneering novel therapeutic approaches by Hanie Raufi, Pouya Zahmatkesh, Sahar Safaei, Ata Bahadori, Saeed Solali (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13396058.txt.
Description
Hanie Raufi and others review CDK9 as a drug target in blood cancers in a 2026 paper. CDK9 drives gene copying stretch-out, feeding short-lived cancer genes and anti-death proteins, and its wild activity shows up in blood cancer, marrow cancer, and big B-cell lymphoma.
Inside the P-TEFb crew, CDK9 tags RNA polymerase II and histones, keeping cancer programs on and breeding drug spurn. Blocking CDK9 hits cancer cells' need for fast gene copying. The review tours first drug blocks and the snag of hitting a cell engine used all over the body with care.
Catalog record
| CREATOR | Hanie Raufi, Pouya Zahmatkesh, Sahar Safaei, Ata Bahadori, Saeed Solali |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |